AUTHOR=Ascari Lucas M. , Rocha Stephanie C. , Gonçalves Priscila B. , Vieira Tuane C. R. G. , Cordeiro Yraima 

TITLE=Challenges and Advances in Antemortem Diagnosis of Human Transmissible Spongiform Encephalopathies

JOURNAL=Frontiers in Bioengineering and Biotechnology

VOLUME=Volume 8 - 2020

YEAR=2020

URL=https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2020.585896

DOI=10.3389/fbioe.2020.585896

ISSN=2296-4185

ABSTRACT=Transmissible spongiform encephalopathies (TSEs), also known as prion diseases, arise from the structural conversion of the monomeric, cellular prion protein (PrPC) into its multimeric scrapie form (PrPSc). These pathologies comprise a group of intractable, rapidly-evolving neurodegenerative diseases. Currently, a definitive diagnosis of TSE relies on the detection of PrPSc and/or the identification of pathognomonic histological features in brain tissue samples, which are usually obtained postmortem or, in rare cases, by brain biopsy (antemortem). Over the past two decades, several paraclinical tests for antemortem diagnosis have been developed to preclude the need for brain samples. Some of these alternative methods have been validated and can provide a probable diagnosis when combined with clinical evaluation. Paraclinical tests include in vitro cell-free conversion techniques, such as protein misfolding cyclic amplification (PMCA) and real-time quaking-induced conversion (RT-QuIC), as well as immunoassays, electroencephalography (EEG), and brain bioimaging methods, such as magnetic resonance imaging (MRI). PrPSc is the main biomarker in TSEs, and the RT-QuIC assay stands out for its ability to detect PrPSc in cerebrospinal fluid (CSF), olfactory mucosa, and dermatome skin samples with high sensitivity and specificity. As a result, PMCA and immunoassays have become progressively less popular for identifying PrPSc. Conversely, the importance of MRI has increased over the years. Other biochemical biomarkers are the proteins 14-3-3 and tau, but they are not specific for TSEs. This paper reviews the techniques employed for definite diagnosis, as well as the clinical and paraclinical methods for possible and probable diagnosis, both those in use currently and those no longer employed. We also discuss current criteria, challenges, and perspectives for TSE diagnoses. An early and accurate diagnosis may allow earlier implementation of strategies to delay or stop the progression of the disease.